TOR Serine-Threonine Kinases

• 

  Subject Areas on Research

  • A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1. 
  • A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. 
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 
  • A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. 
  • AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. 
  • AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes. 
  • ATM functions at the peroxisome to induce pexophagy in response to ROS. 
  • ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. 
  • Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. 
  • Akt-dependent and -independent mechanisms of mTOR regulation in cancer. 
  • Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. 
  • Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. 
  • An animal model of MYC-driven medulloblastoma. 
  • An expanded role of the tumor suppressor TSC1 in T cell tolerance. 
  • An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. 
  • Anabolism-Associated Mitochondrial Stasis Driving Lymphocyte Differentiation over Self-Renewal. 
  • Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. 
  • Association of variants in FRAP1 and PDGFRA with corneal curvature in Asian populations from Singapore. 
  • Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations. 
  • Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. 
  • Autophagy modulates articular cartilage vesicle formation in primary articular chondrocytes. 
  • Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. 
  • BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). 
  • BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. 
  • Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. 
  • Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 
  • Big or fast: two strategies in the developmental control of body size. 
  • Biological Role and Therapeutic Potential of IDH Mutations in Cancer. 
  • Branched-Chain Aminotransferases Control TORC1 Signaling in Saccharomyces cerevisiae. 
  • Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. 
  • Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. 
  • Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3β and TGF-β1-Smad signalling. 
  • Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers. 
  • Cell signaling modifiers in prostate cancer. 
  • Cervical Vagus Nerve Stimulation Improves Neurologic Outcome After Cardiac Arrest in Mice by Attenuating Oxidative Stress and Excessive Autophagy. 
  • Charting the landscape of tandem BRCT domain-mediated protein interactions. 
  • Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. 
  • Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. 
  • Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. 
  • Coming of age: molecular drivers of aging and therapeutic opportunities. 
  • Comprehensive molecular characterization of urothelial bladder carcinoma. 
  • Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. 
  • Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. 
  • Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. 
  • Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. 
  • Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. 
  • Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. 
  • DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. 
  • Death-associated protein kinase 1 promotes growth of p53-mutant cancers. 
  • Decreased autophagy and fuel switching occur in a senescent hepatic cell model system. 
  • Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation. 
  • Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. 
  • Differential controls of MAIT cell effector polarization by mTORC1/mTORC2 via integrating cytokine and costimulatory signals. 
  • Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays. 
  • Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature. 
  • Doublecortin-Like Kinases Promote Neuronal Survival and Induce Growth Cone Reformation via Distinct Mechanisms. 
  • Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. 
  • Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. 
  • Dysregulation of the TSC-mTOR pathway in human disease. 
  • Dysregulation of the mTOR pathway secondary to mutations or a hostile microenvironment contributes to cancer and poor wound healing. 
  • ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. 
  • Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. 
  • Effects of spaceflight on murine skeletal muscle gene expression. 
  • Efficacy and safety of mammalian target of rapamycin inhibitors following intestinal and multivisceral transplantation. 
  • Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. 
  • Essential Role of mTORC1 in Self-Renewal of Murine Alveolar Macrophages. 
  • Everolimus in colorectal cancer. 
  • Everolimus tablets for patients with subependymal giant cell astrocytoma. 
  • Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. 
  • Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. 
  • Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. 
  • Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. 
  • Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. 
  • Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. 
  • Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population. 
  • Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. 
  • Growth signaling at the nexus of stem cell life and death. 
  • Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. 
  • Hepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein Inhibition. 
  • Hyperhomocysteinemia causes ER stress and impaired autophagy that is reversed by Vitamin B supplementation. 
  • IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. 
  • IL-7 enhances the survival and maintains the size of naive T cells. 
  • Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. 
  • Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. 
  • Impaired growth and force production in skeletal muscles of young partially pancreatectomized rats: a model of adolescent type 1 diabetic myopathy? 
  • Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. 
  • Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons. 
  • Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. 
  • Influenza vaccines: mTOR inhibition surprisingly leads to protection. 
  • Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. 
  • Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. 
  • Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. 
  • L-leucine partially rescues translational and developmental defects associated with zebrafish models of Cornelia de Lange syndrome. 
  • LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. 
  • Long-chain omega-3 fatty acids regulate bovine whole-body protein metabolism by promoting muscle insulin signalling to the Akt-mTOR-S6K1 pathway and insulin sensitivity. 
  • Longevity-related molecular pathways are subject to midlife "switch" in humans. 
  • MTOR-independent induction of autophagy in trabecular meshwork cells subjected to biaxial stretch. 
  • MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. 
  • MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. 
  • Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. 
  • Mammalian target of rapamycin inhibition. 
  • Management of adverse events associated with idelalisib treatment: expert panel opinion. 
  • Mechanistic target of rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function. 
  • Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. 
  • Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. 
  • Metformin prevents tobacco carcinogen--induced lung tumorigenesis. 
  • Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. 
  • Microscaled proteogenomic methods for precision oncology. 
  • Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis. 
  • Modulation of Xenogeneic T-cell Proliferation by B7 and mTOR Blockade of T Cells and Porcine Endothelial Cells. 
  • Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 
  • Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. 
  • Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. 
  • Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. 
  • NCCN Task Force Report: mTOR inhibition in solid tumors. 
  • Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. 
  • Negative regulation of mTOR activation by diacylglycerol kinases. 
  • Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors. 
  • Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. 
  • On the Discovery of TOR As the Target of Rapamycin. 
  • PAK1 mediates resistance to PI3K inhibition in lymphomas. 
  • PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. 
  • PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. 
  • PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. 
  • PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. 
  • PTEN hamartoma tumor syndromes. 
  • Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. 
  • Polymorphisms in mTORC1 genes modulate risk of esophageal squamous cell carcinoma in eastern Chinese populations. 
  • Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population. 
  • Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test. 
  • Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. 
  • Rap1 promotes multiple pancreatic islet cell functions and signals through mammalian target of rapamycin complex 1 to enhance proliferation. 
  • Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. 
  • Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. 
  • Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. 
  • Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. 
  • Receptor signaling in immune cell development and function. 
  • Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells. 
  • Regulation of T-cell survival and mitochondrial homeostasis by TSC1. 
  • Regulation of mast cell survival and function by tuberous sclerosis complex 1. 
  • Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. 
  • Reply to M A Khattak et al. 
  • Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. 
  • Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. 
  • Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. 
  • Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. 
  • Skeletal muscle mass recovery from atrophy in IL-6 knockout mice. 
  • Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. 
  • Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. 
  • Somatic variants in diverse genes leads to a spectrum of focal cortical malformations. 
  • Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. 
  • Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. 
  • Sustained activation of mTORC1 in macrophages increases AMPKα-dependent autophagy to maintain cellular homeostasis. 
  • Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. 
  • Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. 
  • T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. 
  • TGF-beta: a new role for an old AktTOR. 
  • TRPC1 channels are critical for hypertrophic signaling in the heart. 
  • TSC1 Promotes B Cell Maturation but Is Dispensable for Germinal Center Formation. 
  • Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. 
  • Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. 
  • Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. 
  • Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle. 
  • The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease. 
  • The Human FSGS-Causing ANLN R431C Mutation Induces Dysregulated PI3K/AKT/mTOR/Rac1 Signaling in Podocytes. 
  • The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation. 
  • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. 
  • The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. 
  • The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. 
  • The mammalian class 3 PI3K (PIK3C3) is required for early embryogenesis and cell proliferation. 
  • The monomeric receptor binding domain of tetrameric α2-macroglobulin binds to cell surface GRP78 triggering equivalent activation of signaling cascades. 
  • The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. 
  • The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. 
  • The role and regulation of mTOR in T-lymphocyte function. 
  • The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. 
  • The role of diacylglycerol kinase ζ and phosphatidic acid in the mechanical activation of mammalian target of rapamycin (mTOR) signaling and skeletal muscle hypertrophy. 
  • The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. 
  • The role of tuberous sclerosis complex 1 in regulating innate immunity. 
  • Therapeutic Benefit of Autophagy Modulation in Pompe Disease. 
  • Therapy for non-clear cell histologies in renal cancer. 
  • Thyroid Hormone Stimulation of Autophagy Is Essential for Mitochondrial Biogenesis and Activity in Skeletal Muscle. 
  • Thyroid hormone (T3) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy. 
  • Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. 
  • Titin truncations lead to impaired cardiomyocyte autophagy and mitochondrial function in vivo. 
  • Tuberous sclerosis complex is a novel, amyloid-independent tauopathy associated with elevated phosphorylated 3R/4R tau aggregation. 
  • Tumor suppressor TSC1 is critical for T-cell anergy. 
  • Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. 
  • Vesicular Trafficking Systems Impact TORC1-Controlled Transcriptional Programs in Saccharomyces cerevisiae. 
  • Vibrio vulnificus induces mTOR activation and inflammatory responses in macrophages. 
  • iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions. 
  • mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK. 
  • mTOR and its tight regulation for iNKT cell development and effector function. 
  • mTOR coordinates transcriptional programs and mitochondrial metabolism of activated Treg subsets to protect tissue homeostasis. 
  • mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 
  • mTOR is critical for intestinal T-cell homeostasis and resistance to Citrobacter rodentium. 
  • mTORC1 and mTORC2 Kinase Signaling and Glucose Metabolism Drive Follicular Helper T Cell Differentiation. 
  • mTORC1 in Thymic Epithelial Cells Is Critical for Thymopoiesis, T-Cell Generation, and Temporal Control of γδT17 Development and TCRγ/δ Recombination. 
  • mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. 
  • mTORC2 in Thymic Epithelial Cells Controls Thymopoiesis and T Cell Development. 
  • miR-19 is a key oncogenic component of mir-17-92. 
• 

  Keywords of People

  • Buckley, Anne Frances, Assistant Professor of Pathology, Pathology
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Pharmacology & Cancer Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Zhong, Xiaoping, Professor of Pediatrics, Immunology